533 Bryant Street
57 articles with Horizon Therapeutics
4/2/2020Biopharma companies from across the globe provide updates on their pipelines and business practices.
TEPEZZA™ (teprotumumab-trbw) Significantly Reduces Proptosis (Eye Bulging), a Key Marker of Thyroid Eye Disease, Across Patient Subtypes
Data presented as part of ENDO 2020 demonstrates proptosis response regardless of age, gender and smoking status
3/9/2020Although March looks to be a busy month for the U.S. Food and Drug Administration, several of the PDUFA dates for this week were for drugs under Priority Review.
Horizon Therapeutics plc Launches the Down and Out Kidney Campaign to Call Attention to the Prevalence and Impact of Gout in Chronic Kidney Disease
Recent Data Supports Urgent Need to Address Uric Acid Accumulation and Protect the Kidney
These prices refer to the company’s list price. Most patients will not pay that price because of various forms of health insurance or patient assistance programs.
Horizon Therapeutics plc to Release Fourth-Quarter and Full-Year 2019 Financial Results and Host Webcast on Feb. 26, 2020
Horizon Therapeutics plc announced that its fourth-quarter and full-year 2019 financial results will be released on Wednesday, Feb. 26, 2020.
Horizon Therapeutics plc announced changes to its research and development organization structure.
The New England Journal of Medicine Publishes Comprehensive Data from Phase 3 Clinical Trial (OPTIC) of TEPEZZA™ (teprotumumab-trbw) for Thyroid Eye Disease
Phase 3 trial achieved its primary endpoint and all secondary endpoints with marked improvement in key indicators of disease
1/20/2020There were plenty of clinical trial announcements this week. Here's a look.
1/16/2020Companies from across the globe provide updates to their business and pipeline.
Rosalind Franklin University of Medicine and Science announced that its new Helix 51 incubator has garnered corporate support from Horizon Therapeutics.
MIRROR Open-Label Study Topline Data of Methotrexate with KRYSTEXXA (pegloticase injection) Indicates Significant Improvement in Response Rate
Horizon Therapeutics plc announced topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® provided an increased durability of response for people living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
Horizon Therapeutics plc Increases Peak U.S. Annual Net Sales Expectations for Key Growth Drivers; Provides Update on Several Pipeline Programs
Horizon Therapeutics plc announced that it is increasing the peak U.S. annual net sales expectations for its key growth drivers KRYSTEXXA and teprotumumab, as well as providing several pipeline updates..
11/18/2019It was a busy week for clinical trial announcements. Here’s a look.
Third-Quarter 2019 Net Sales of $335.5 Million Increased 3 Percent; Third-Quarter 2019 GAAP Net Income of $18.2 Million; Adjusted EBITDA of $130.4 Million
Horizon Therapeutics plc Brings Gout-Kidney Link into Focus during American Society of Nephrology (ASN) Kidney Week 2019
Research, interactive features and charitable opportunity support advancement of care
AVISE® MTX Test from Exagen Supports Horizon Therapeutics plc Clinical Trial to Evaluate Pegloticase with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout
Exagen Inc., is pleased to announce clinical study support for Horizon Therapeutics plc to measure methotrexate polyglutamates, the active metabolites of methotrexate in the MIRROR Randomized Controlled Trial Study.
10/17/2019Companies from across the globe provide business and pipeline updates.
For World Sight Day, Horizon and Prevent Blindness Are Calling on the Thyroid Eye Disease (TED) Community to Put “Vision First”
Text the word “EYE” to 56512 to generate a donation from Horizon to Prevent Blindness to fund TED education
Current Executive Vice President and Chief Business Officer, Robert F. Carey, will Retire Effective Oct. 1.